CIBC Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $398K | Hold |
5,017
| – | – | ﹤0.01% | 906 |
|
|
2026
Q1 | $377K | Hold |
5,017
| – | – | ﹤0.01% | 886 |
|
|
2025
Q4 | $397K | Buy |
5,017
+409
| +9% | +$30.8K | ﹤0.01% | 865 |
|
|
2025
Q3 | $301K | Buy |
+4,608
| New | +$225K | ﹤0.01% | 934 |
|
|
2024
Q1 | – | Sell |
-4,002
| Closed | -$202K | – | 1139 |
|
|
2023
Q4 | $202K | Buy |
+4,002
| New | +$192K | ﹤0.01% | 997 |
|
|
2022
Q4 | – | Sell |
-5,203
| Closed | -$230K | – | 1163 |
|
|
2022
Q3 | $230K | Buy |
+5,203
| New | +$219K | ﹤0.01% | 1008 |
|
|
2022
Q2 | – | Sell |
-5,583
| Closed | -$207K | – | 1376 |
|
|
2022
Q1 | $207K | Buy |
+5,583
| New | +$183K | ﹤0.01% | 1363 |
|
|
2021
Q3 | – | Sell |
-5,140
| Closed | -$205K | – | 1477 |
|
|
2021
Q2 | $205K | Hold |
5,140
| – | – | ﹤0.01% | 1275 |
|
|
2021
Q1 | $231K | Sell |
5,140
-106
| -2% | -$5.91K | ﹤0.01% | 1141 |
|
|
2020
Q4 | $297K | Hold |
5,246
| – | – | ﹤0.01% | 906 |
|
|
2020
Q3 | $249K | Buy |
5,246
+130
| +3% | +$7.22K | ﹤0.01% | 909 |
|
|
2020
Q2 | $302K | Hold |
5,116
| – | – | ﹤0.01% | 799 |
|
|
2020
Q1 | $242K | Hold |
5,116
| – | – | ﹤0.01% | 801 |
|
|
2019
Q4 | $309K | Buy |
5,116
+613
| +14% | +$36.5K | ﹤0.01% | 867 |
|
|
2019
Q3 | $270K | Hold |
4,503
| – | – | ﹤0.01% | 885 |
|
|
2019
Q2 | $289K | Hold |
4,503
| – | – | ﹤0.01% | 871 |
|
|
2019
Q1 | $366K | Hold |
4,503
| – | – | ﹤0.01% | 785 |
|
|
2018
Q4 | $243K | Hold |
4,503
| – | – | ﹤0.01% | 856 |
|
|
2018
Q3 | $232K | Buy |
+4,503
| New | +$212K | ﹤0.01% | 980 |
|
|
2018
Q1 | – | Sell |
-4,190
| Closed | -$211K | – | 1073 |
|
|
2017
Q4 | $211K | Hold |
4,190
| – | – | ﹤0.01% | 986 |
|
|
2017
Q3 | $212K | Buy |
+4,190
| New | +$219K | ﹤0.01% | 939 |
|
|
2016
Q1 | – | Sell |
-3,637
| Closed | -$225K | – | 955 |
|
|
2015
Q4 | $225K | Buy |
+3,637
| New | +$196K | ﹤0.01% | 823 |
|
|
2015
Q3 | – | Sell |
-3,637
| Closed | -$209K | – | 956 |
|
|
2015
Q2 | $209K | Buy |
3,637
+117
| +3% | +$7.44K | ﹤0.01% | 898 |
|
|
2015
Q1 | $224K | Buy |
3,520
+210
| +6% | +$14.2K | ﹤0.01% | 870 |
|
|
2014
Q4 | $204K | Buy |
+3,310
| New | +$163K | ﹤0.01% | 879 |
|
Other funds holding IONS
CIBC Asset Management's IONS Position: Q2 2026 in Review
CIBC Asset Management held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 5,017 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #906.
CIBC Asset Management first reported a position in IONS in Q4 2014 and has held it in 25 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- CIBC Asset Management held 5,017 shares of Ionis Pharmaceuticals worth $398K as of Q2 2026.
- CIBC Asset Management left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
- Ionis Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q2 2026, its #906 holding.
- CIBC Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2014 and has held it in 25 quarters since.
- 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.